Neoplasms
Conditions
Brief summary
This clinical trial studies the best time to administer the influenza vaccine to patients with non-hematologic malignancies receiving chemotherapy. Giving the vaccine at different times relative to chemotherapy may affect how well it works to help the body build an immune response and prevent influenza in these patients.
Interventions
BIOLOGICALtrivalent influenza vaccine
Sponsors
National Cancer Institute (NCI)
Washington University School of Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have biopsy-confirmed non-hematological malignancy * Patients must be scheduled to receive cytotoxic chemotherapy (adjuvant or metastatic setting), excluding immunotherapy * Patients must be of age \>=18 years. * Patients must have an absolute lymphocyte count \>= 1,000/mcL immediately prior to influenza vaccination * Ability of the patient (or legally authorized representative if applicable) to understand and the willingness to sign a written informed consent document
Exclusion criteria
* Patients who have already received the influenza vaccine during the season in which they are considered for eligibility will be excluded * History of allergic reactions attributed to compounds of similar chemical or biologic composition to the influenza vaccine or egg allergies * Previous history of Guillian-Barre syndrome within the previous 6 weeks to influenza vaccination * Patients must not be receiving chronic steroid therapy, defined as \>= 14 days, unless used as part of a chemotherapy regimen * Patients must not be on any other agents that can suppress the immune system * Planned concurrent therapy with radiation * Uncontrolled illness at time of enrollment or influenza vaccination including, but not limited to, ongoing or active febrile illness * Psychiatric illness/social situations that would limit compliance with study requirements * Known immunosuppression eg. history of organ transplantation or known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because they may not be able to mount an appropriate immune response * History of influenza-like illness, defined as a temperature \> 37.8 degree C with cough or sore throat starting October 1, 2011 throughout the duration of the study * Patient may not be scheduled to receive chemotherapy on a weekly basis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Optimal timing of seasonal influenza vaccination with regard to chemotherapy administration schedule. | 4 weeks from the influenza vaccine | We will assess co-primary endpoints of serologic response to the H3N2 and H1N1 strains in the 2011-2012 and 2012-2013 seasonal influenza vaccine. |
Secondary
| Measure | Time frame |
|---|---|
| Report the presence of post-vaccination adverse events | 4 weeks from the influenza vaccine |
Countries
United States
Outcome results
None listed